Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study

Neurology ◽  
2008 ◽  
Vol 70 (Issue 16, Part 2) ◽  
pp. 1423-1430 ◽  
Author(s):  
J. A. Driver ◽  
T. Kurth ◽  
J. E. Buring ◽  
J. M. Gaziano ◽  
G. Logroscino
Keyword(s):  
Cohort Study ◽  
Parkinson Disease ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Risk Of Mortality

scholarly journals Increased hazard of mortality in cases compatible with SARS-CoV-2 variant of concern 202012/1 - a matched cohort study

2021 ◽  
Author(s):  
Robert Challen ◽  
Ellen Brooks-Pollock ◽  
Jonathan M Read ◽  
Louise Dyson ◽  
Krasimira Tsaneva-Atanasova ◽  
...  
Keyword(s):  
Cohort Study ◽  
Capacity Planning ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Mortality Hazard ◽  
Risk Of Mortality ◽  
New Variant ◽  
Proxy Measure ◽  
Index Of Multiple Deprivation ◽  
Mortality Hazard Ratio

AbstractObjectivesTo establish whether there is any change in mortality associated with infection of a new variant of SARS-CoV-2 (VOC-202012/1), first detected in UK in December 2020, compared to that associated with infection with circulating SARS-CoV-2 variants.DesignMatched cohort study. Cases are matched by age, gender, ethnicity, index of multiple deprivation, lower tier local authority region, and sample date of positive specimen, and differing only by detectability of the spike protein gene using the TaqPath assay - a proxy measure of VOC-202012/1 infection.SettingUnited Kingdom, Pillar 2 COVID-19 testing centres using the taqPath assay.Participants54,773 pairs of participants testing positive for SARS-CoV-2 in Pillar 2 between 1st October 2020 and 29th January 2021.Main outcome measures - Death within 28 days of first positive SARS-CoV-2 test.ResultsThere is a high probability that the risk of mortality is increased by infection with VOC-202012/01 (p <0.001). The mortality hazard ratio associated with infection with VOC-202012/1 compared to infection with previously circulating variants is 1.7 (95% CI 1.3 - 2.2) in patients who have tested positive for COVID-19 in the community. In this comparatively low risk group, this represents an increase of deaths from 1.8 in 1000 to 3.1 in 1000 detected cases.ConclusionsIf this finding is generalisable to other populations, VOC-202012/1 infections have the potential to cause substantial additional mortality over and previously circulating variants. Healthcare capacity planning, national and international control policies are all impacted by this finding, with increased mortality lending weight to the argument that further coordinated and stringent measures are justified to reduce deaths from SARS-CoV-2.

scholarly journals SP632PROTON PUMP INHIBITOR USAGE, HYPOMAGNESEMIA AND RISK OF MORTALITY IN HEMODIALYSIS PATIENTS: A PROPENSITY SCORE MATCHED COHORT STUDY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii348-iii349
Author(s):  
Angel Martín de Francisco ◽  
Rosa Ramos ◽  
Javier Varas ◽  
José Merello ◽  
Bernard Canaud ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Hemodialysis Patients ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Risk Of Mortality

scholarly journals Recorded Penicillin Allergy and Risk of Mortality: a Population-Based Matched Cohort Study

2019 ◽  
Vol 34 (9) ◽  
pp. 1685-1687 ◽  
Author(s):  
Kimberly G. Blumenthal ◽  
Na Lu ◽  
Yuqing Zhang ◽  
Rochelle P. Walensky ◽  
Hyon K. Choi
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Penicillin Allergy ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Risk Of Mortality

scholarly journals Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

BMJ ◽  
2021 ◽  
pp. n579
Author(s):  
Robert Challen ◽  
Ellen Brooks-Pollock ◽  
Jonathan M Read ◽  
Louise Dyson ◽  
Krasimira Tsaneva-Atanasova ◽  
...  
Keyword(s):  
Cohort Study ◽  
Capacity Planning ◽  
Matched Cohort ◽  
Community Based ◽  
Matched Cohort Study ◽  
Risk Of Mortality ◽  
New Variant ◽  
Proxy Measure ◽  
The Uk ◽  
Index Of Multiple Deprivation

Abstract Objective To establish whether there is any change in mortality from infection with a new variant of SARS-CoV-2, designated a variant of concern (VOC-202012/1) in December 2020, compared with circulating SARS-CoV-2 variants. Design Matched cohort study. Setting Community based (pillar 2) covid-19 testing centres in the UK using the TaqPath assay (a proxy measure of VOC-202012/1 infection). Participants 54 906 matched pairs of participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021, followed-up until 12 February 2021. Participants were matched on age, sex, ethnicity, index of multiple deprivation, lower tier local authority region, and sample date of positive specimens, and differed only by detectability of the spike protein gene using the TaqPath assay. Main outcome measure Death within 28 days of the first positive SARS-CoV-2 test result. Results The mortality hazard ratio associated with infection with VOC-202012/1 compared with infection with previously circulating variants was 1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community. In this comparatively low risk group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases. Conclusions The probability that the risk of mortality is increased by infection with VOC-202012/01 is high. If this finding is generalisable to other populations, infection with VOC-202012/1 has the potential to cause substantial additional mortality compared with previously circulating variants. Healthcare capacity planning and national and international control policies are all impacted by this finding, with increased mortality lending weight to the argument that further coordinated and stringent measures are justified to reduce deaths from SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document